PARP1 and small cell lung carcinoma: Similarly, Pietanza et al. found a considerable improvement in ORR with TMZ and veliparib in patients receiving this combination, where SLFN11 expression in tumors was related to better PFS and OS, indicating a predictive biomarker of PARP-inhibitor sensitivity in SCLC [94].